Targeting the Immune System and Beyond: The Potential for Safe and Durable Responses in Higher-Risk Myelodysplastic Syndromes with Immuno-Myeloid Therapy
The hypomethylating agents (HMA), azacitidine and decitabine, are currently regarded as the standard of care for patients with…